Anti-vascularendothelialgrowthfactortherapyforneovascularoculardiseasesotherthanage-relatedmaculardegeneration
ThomasA.CiullaaandPhilipJ.Rosenfeldb
VitreoretinalService,MidwestEyeInstitute,Indianapolis,IndianaandbDepartmentofOphthalmology,BascomPalmerEyeInstitute,
UniversityofMiamiMillerSchoolofMedicine,Miami,Florida,USA
CorrespondencetoThomasA.Ciulla,MD,VitreoretinalService,MidwestEyeInstitute,201PennsylvaniaParkway,Indianapolis,IN46280,USA
Tel:+13175060334;fax:+13178171898;e-mail:thomasciulla@yahoo.com
CurrentOpinioninOphthalmology2009,20:166–174
a
Purposeofreview
Anti-vascularendothelialgrowthfactor(anti-VEGF)therapiesthatarrestchoroidalangiogenesisandreducevascularpermeabilityhaverevolutionizedclinicalpracticesforneovasculareyediseases.Thisreviewdescribesanti-VEGFstrategiesthatarebeingevaluatedinoculardiseases,otherthanneovascularage-relatedmaculardegeneration,inwhichneovascularizationplaysacriticalroleinpathogenesis.Recent ndings
Earlystudiesoftheanti-VEGFagents,pegaptanibsodium,ranibizumab,bevacizumab,VEGFtrap,andbevasiranibinthetreatmentofvariousneovasculardiseases(e.g.,diabeticmacularedema,retinalveinocclusion,choroidalneovascularization)haveshownpromisingresults.Theef cacyandsafetyoftheseagents,eitheraloneorcombinedwithstandardtreatments(e.g.,laserphotocoagulation),anti-in ammatoryagents,orothernon-VEGF-basedantiangiogenictherapies,isactivelyinvestigated.Non-VEGF-drivenpathwaysandgrowthfactorsotherthanVEGFmayplayimportantrolesinpathogenesisandareincludedincertaincombinationtherapieswithVEGFinhibitors.Summary
ThediscoveryofVEGF-A’sroleinthepathogenesisofneovascularoculardiseaseprovidedastrongrationaleforthedevelopmentofanti-VEGF-basedtherapies.Thereisnowampleevidencethatanti-VEGFtherapiesareviabletreatmentoptionsforthesediseases.Nevertheless,large,randomizedcontrolledtrialsarestillawaitedtocon rmearlysafetyandef cacy ndingsfromsmall,open-labelprospectivestudies.Keywords
anti-vascularendothelialgrowthfactortherapy,bevacizumab,neovascularization,pegaptanibsodium,ranibizumab
CurrOpinOphthalmol20:166–174
ß2009WoltersKluwerHealth|LippincottWilliams&Wilkins1040-8738
Introduction
Thesuccessofanti-vascularendothelialgrowthfactor(VEGF)therapiesinneovascularage-relatedmaculardegeneration(AMD)hasspurredinvestigationofsimilartreatmentstrategiesforotherexudativeoculardiseasesdescribedinTable1[1 ,2–7,8 ,9,10,11 ,12 ,13–25].Theseincludeproliferativediabeticretinopathy(PDR)[1 ,3–7],diabeticmacularedema(DME)[2],retinalveinocclusion(RVO)[8 ,9,10,11 ,12 ,13–15],andretino-pathyofprematurity(ROP)[16,17].Currenttreatmentoptionsforthesediseasesandtheircomplicationsarelimited,consistingprimarilyoflaserphotocoagulationandvitrectomy[2,15,26].Althoughthesetreatmentsgenerallyreducelossofvisualacuity,particularlyforpatientswithclinicallysigni cantDME,theyaredestructive(e.g.,laser),associatedwithundesirablesideeffects,andtreatonlythelaterstagesofthedisease[2].
1040-8738ß2009WoltersKluwerHealth|LippincottWilliams&Wilkins
Vascularendothelialgrowthfactor-targetedtherapies
Earlypreclinical[27–30]andclinical[31–34]studieshaveimplicatedVEGFasamajorfactorinthepatho-genesisofneovasculareyediseases,buildingtheration-aleforfurtherinvestigationofthetherapeuticpotentialofVEGF-targetedagents.Anti-VEGF-basedtherapiescur-rentlyunderinvestigationfortheiref cacyandsafetyinneovasculardiseasesotherthanAMDincludetheapta-mer,pegaptanibsodium;theVEGF-speci cantibodies,ranibizumab,andbevacizumab;theimmunoglobulinG(IgG)-VEGFreceptorfusionproteinVEGFtrap;andthesmallinterferingRNA(siRNA)bevasiranib(Table2).Additionally,certainantiangiogeniccorticosteroidsthatdonotspeci callytargetVEGF,suchastriamcinolone,dexamethasone,and uocinoloneacetonidearealsobeingusedandevaluatedforoculardiseases.
DOI:10.1097/ICU.0b013e328329d173
therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and ...
anti-vascular endothelial growth factor (VEGF) ...found in human plasma and serum and ocular ...(Avastin) therapy for neovascular age-related ...
anti-vascular endothelial growth factor therapy – bevacizumab Acta Ophthalmol....It has been known that ocular diseases in which in?ammatory and autoimmune...
therapy or having an accompanying ocular disease. ...therapy for neovascular age - related macular ... an anti-vascular endothelial growth factor antigen...
(Macugen ) TM 1 The Impact of Neovascular AMD ...Injection – First Anti-VEGF Therapy for the Eye...Vascular Endothelial Growth Factor (VEGF) Vascular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
anti-vascular endothelial growth factor fusion ...Thus, with one injection of KH902, neovascular ...Both of them could inhibit the ocular ...
热门文档